Description
Product Description
PT-141, also known as Bremelanotide, is a synthetic peptide that functions as a melanocortin receptor agonist. It was initially developed as a treatment for sexual dysfunction, specifically for individuals with hypoactive sexual desire disorder (HSDD).
PT-141 acts on melanocortin receptors in the central nervous system, stimulating the release of neurotransmitters involved in sexual arousal and desire. It increases dopamine activity, which plays a crucial role in regulating sexual motivation and pleasure.
Unlike other medications for sexual dysfunction, PT-141 does not target the vascular system but acts directly on the brain to enhance sexual desire.
It is administered as a subcutaneous injection and typically begins to take effect within a few hours.
Studies have shown that PT-141 has potential benefits for both men and women, addressing various forms of sexual dysfunction. It has demonstrated efficacy in improving sexual desire, arousal, and satisfaction
The science
The science behind PT-141 (Bremelanotide) involves its interaction with melanocortin receptors in the brain.
PT-141 is a peptide that acts as a selective agonist for the melanocortin-4 receptor (MC4R) and, to a lesser extent, the melanocortin-3 receptor (MC3R). These receptors are found in the central nervous system and play a role in regulating sexual arousal and desire.
When PT-141 binds to the MC4R and MC3R, it activates a signaling cascade that leads to the release of various neurotransmitters, including dopamine, in the brain. Dopamine is involved in the reward and pleasure pathways and plays a significant role in sexual motivation and desire.
By increasing dopamine activity, PT-141 enhances sexual arousal and desire. It helps to address sexual dysfunction by improving the neurochemical processes involved in sexual response.
PT-141 is different from traditional treatments for sexual dysfunction, such as phosphodiesterase type 5 (PDE5) inhibitors like Viagra. While PDE5 inhibitors primarily target the vascular system to improve blood flow, PT-141 acts directly on the brain to enhance sexual desire.
Key benefits
- Increases sexual desire and arousal
- Enhances sexual pleasure and satisfaction
- Addresses sexual dysfunction, including hypoactive sexual desire disorder (HSDD)
- Acts directly on the brain to improve sexual motivation
- Potential benefits for both men and women
- Administered through subcutaneous injection
Dosage protocol
Peptide: PT-141
Vial size: 10mg
Recommended dose: 1mg (may increase to 4mg for individuals with erectile dysfunction)
Administration frequency: Once every 24 hours, with a maximum of 8 doses per month
Administration timing: 45 minutes before adult activity
Onset of effects: Effects may be noticeable within minutes to a few hours
Duration of effects: Effects may last up to 24 hours, with some men reporting longer-lasting erections of 2-6 hours
Product FAQ
PT-141 works by stimulating melanocortin receptors in the brain, specifically the melanocortin-4 receptor (MC4R). By activating these receptors, PT-141 enhances the release of dopamine, a neurotransmitter involved in sexual motivation and desire.
Yes, PT-141 has shown potential benefits for both men and women. It can address sexual dysfunction and increase sexual desire in individuals of both genders.
